Chai C.-A., Teoh Y.-C., Tailly T., Emiliani E., Inoue T., Tanidir Y., Gadzhiev N., Bin Hamri S., Ong W.L., Shrestha A., Ragoori D., Lakmichi M.A., Gorelov D., Soebhali B., Vaddi C.M., Bhatia T.P., Desai D., Durai P., Heng C.-T., Chew B., Castellani D., Somani B., Traxer O., Gauhar V.. Influence of pre-stenting on RIRS outcomes. Inferences from patients of the Global Multicentre Flexible Ureteroscopy Outcome Registry (FLEXOR). Minerva Urology And Nephrology. 2023; 75(4)DOI:10.23736/S2724-6051.23.05239-4. PMID:37293816. IF:4.900(Q1/2D).

Esperto F., Pietropaolo A., Emiliani E., de Coninck V., Tailly T., Keller E.X., Talso M., Tonyali S., Sener E.T., Zeeshan Hameed B.M., Tzelves L., Ventimiglia E., Juliebø-Jones P., Faiella E., Mykoniatis I., Tsaturyan A., Scarpa R.M.. Quality of life of patients with stone disease: timing, planning, strategies, and prevention of a systemic pathology. Minerva Urology And Nephrology. 2023; 75(4)DOI:10.23736/S2724-6051.23.05435-6. PMID:37314814. IF:4.900(Q1/2D).

Sanz Gómez I., Huguet J., Bravo A., Robalino J., Rodríguez Faba Ó., Territo Á., Gaya J.M., Palou J., Breda A.. Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure. Clinical Genitourinary Cancer. 2023; 21(4)DOI:10.1016/j.clgc.2023.03.002. PMID:37076337. IF:2.300(Q2/5D).

Grobet-Jeandin E., Lenfant L., Mir C., Giannarini G., Alcaraz A., Albersen M., Breda A., Briganti A., Rouprêt M., Seisen T., EAU Section of Oncological Urology (ESOU) Board. A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer. European Urology Oncology. 2023; 6(3)DOI:10.1016/j.euo.2023.02.008. PMID:36906510. IF:8.300(Q1/1D).